These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 1980270)

  • 41. The pharmacologic treatment of neuroleptic-induced akathisia.
    Fleischhacker WW; Roth SD; Kane JM
    J Clin Psychopharmacol; 1990 Feb; 10(1):12-21. PubMed ID: 1968470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Three cases of akathisia and "acting out".
    Siris SG
    J Clin Psychiatry; 1985 Sep; 46(9):395-7. PubMed ID: 2863258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Akathisia: clinical phenomenology and relationship to tardive dyskinesia.
    Kahn EM; Munetz MR; Davies MA; Schulz SC
    Compr Psychiatry; 1992; 33(4):233-6. PubMed ID: 1353716
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship between neuroleptic extrapyramidal syndromes and patients' all-cause mortality.
    Modestin J; Vogt Wehrli M; Stephan PL; Agarwalla P
    Pharmacopsychiatry; 2009 Mar; 42(2):57-60. PubMed ID: 19308879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuroleptic-induced akathisia treated with pindolol.
    Reiter S; Adler L; Erle S; Duncan E
    Am J Psychiatry; 1987 Mar; 144(3):383-4. PubMed ID: 2881493
    [No Abstract]   [Full Text] [Related]  

  • 46. L-tryptophan in neuroleptic-induced akathisia.
    Kramer MS; DiJohnson C; Davis P; Dewey DA; DiGiambattista S
    Biol Psychiatry; 1990 Mar; 27(6):671-2. PubMed ID: 1969752
    [No Abstract]   [Full Text] [Related]  

  • 47. Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia.
    Jung HY; Kim JH; Ahn YM; Kim SC; Hwang SS; Kim YS
    Hum Psychopharmacol; 2005 Jan; 20(1):41-5. PubMed ID: 15565639
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia.
    Barnes TR
    Psychiatr Dev; 1987; 5(4):301-19. PubMed ID: 2895467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of clonidine in treating neuroleptic-induced akathisia.
    Zubenko GS; Cohen BM; Lipinski JF; Jonas JM
    Psychiatry Res; 1984 Nov; 13(3):253-9. PubMed ID: 6152054
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia.
    Fleischhacker WW; Bergmann KJ; Perovich R; Pestreich LK; Borenstein M; Lieberman JA; Kane JM
    Psychopharmacol Bull; 1989; 25(2):222-6. PubMed ID: 2574895
    [No Abstract]   [Full Text] [Related]  

  • 51. Handedness as a risk factor for neuroleptic-induced movement disorders.
    Brown KW; White T; Anderson F; McGilp R
    Biol Psychiatry; 1992 Apr; 31(7):746-8. PubMed ID: 1350923
    [No Abstract]   [Full Text] [Related]  

  • 52. Studies on the time course and efficacy of beta-blockers in neuroleptic-induced akathisia and the akathisia of idiopathic Parkinson's disease.
    Adler LA; Angrist B; Weinreb H; Rotrosen J
    Psychopharmacol Bull; 1991; 27(2):107-11. PubMed ID: 1681561
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antipsychotic-withdrawal akathisia versus antipsychotic-induced akathisia: further evidence for the existence of tardive akathisia.
    Dufresne RL; Wagner RL
    J Clin Psychiatry; 1988 Nov; 49(11):435-8. PubMed ID: 2903141
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Case report of propranolol (Inderal) pharmacotherapy for neuroleptic-induced akathisia and tremor.
    Kulik AV; Wilbur R
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(2-3):223-5. PubMed ID: 6137028
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of tolerance to the therapeutic effect of amantadine on akathisia.
    Zubenko GS; Barreira P; Lipinski JF
    J Clin Psychopharmacol; 1984 Aug; 4(4):218-20. PubMed ID: 6470196
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship between negative symptoms in chronic schizophrenia and neuroleptic dose, plasma levels and side effects.
    Schizophr Res; ; . PubMed ID: 9176929
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.